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ROsteoporosis Is a Major
Confounder in Observational
Studies Investigating
Bisphosphonate Therapy
in Aortic Stenosis
We read the paper “Do Bisphosphonates Slow the Progression of
Aortic Stenosis” by Aksoy et al. (1) with great interest. Given the
central role that calcification plays in the progression of aortic
stenosis, the question as to whether bisphosphonates might favor-
ably modify this disease process is an important one.
In their large retrospective study, the researchers found that there
was no difference in aortic stenosis progression between women who
were taking and not taking bisphosphonate therapy after a median
follow-up of 1.6 years. This lack of effect persisted even after
sophisticated propensity matching; however, we believe that this
analysis did not correct for one potentially important confounder.
The link between osteoporosis and increased vascular calcifica-
tion, the so-called calcification paradox, is well established, and the
researchers themselves previously extended this principle to aortic
valve calcification (2–4). We therefore believe that the presence of
osteoporosis in those prescribed bisphosphonate therapy may have
had a significant incremental effect on aortic stenosis progression.
As such, the lack of difference between the groups could be
interpreted as a sign that bisphosphonates were in fact successful in
normalizing disease progression in these patients.
In our opinion, it is unlikely that observational studies will be
able to disentangle the effects of bisphosphonates and osteoporosis
on aortic stenosis. The true impact of these drugs will only become
clear within the setting of a randomized controlled trial.
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Reply
We thank the correspondents for their interesting comment on our
recent paper (1). We would like to point out, however, that none
of the authors of the present paper have been associated with the
papers that they referenced. The calcification paradox whereby
vascular calcification is more prevalent in those with reduced bone
density or increased bone turnover has been well described.
Increased valvular calcification has also been described in patients
with osteoporosis, but specific data on whether osteoporosis
accelerates aortic stenosis progression has not to our knowledge
been reported. Additionally, we have no way of knowing whether
the elderly women in our study who did not receive bisphospho-
nates had some degree of osteoporosis. The fact that many were
receiving vitamin D and calcium supplementation suggests that a
proportion at least were considered at risk for osteoporosis. The
correspondents’ contention that bisphosphonates in our study may
have normalized an acceleration of aortic stenosis associated with
osteoporosis is therefore interesting but still hypothetical. We
agree with the correspondents and stated in our conclusions to the
paper that prospective clinical trials of specific bisphosphonates
will be needed to fully answer the question of the impact of this
class of drugs on aortic stenosis progression.
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Challenging Interpretation of
Elevated Cardiac Troponin T
in a Complex Case
With Rhabdomyolysis
We read with interest the correspondence letter by Sribhen et al.
(1) referring to the article “Diseased skeletal muscle: a noncar-
